PUBLISHER: The Business Research Company | PRODUCT CODE: 1949801
PUBLISHER: The Business Research Company | PRODUCT CODE: 1949801
Autoimmune Gastrointestinal Dysmotility Global Market Report 2026
Autoimmune gastrointestinal dysmotility (AGID) is a rare condition in which the immune system attacks the nerves that control digestive tract movement. This results in slowed or abnormal motility, leading to symptoms such as nausea, bloating, constipation, or intestinal blockage. AGID is often linked to other autoimmune disorders or can occur as a paraneoplastic syndrome.
The primary treatments for autoimmune gastrointestinal dysmotility include medications, surgical interventions, dietary management, and physical therapy. Medications are used to manage AGID by reducing inflammation and improving digestive tract motility. Drug classes include prokinetic agents, anti-inflammatory drugs, immunosuppressive drugs, and antibiotics. Conditions associated with AGID include gastroparesis, chronic intestinal pseudo-obstruction (CIPO), functional dyspepsia, irritable bowel syndrome (IBS), and celiac disease. These medications are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels, and are utilized by hospitals, clinics, home care settings, and research institutions.
Tariffs have affected the autoimmune gastrointestinal dysmotility market by increasing the cost of imported immunosuppressive drugs, prokinetic agents, and nutritional therapy components. These impacts have been most pronounced in medication and dietary management segments, particularly in north america and europe where treatment inputs are globally sourced. Asia-pacific markets have faced cost pressures. However, tariffs have supported localized manufacturing of supportive gastrointestinal therapies.
The autoimmune gastrointestinal dysmotility market research report is one of a series of new reports from The Business Research Company that provides autoimmune gastrointestinal dysmotility market statistics, including autoimmune gastrointestinal dysmotility industry global market size, regional shares, competitors with a autoimmune gastrointestinal dysmotility market share, detailed autoimmune gastrointestinal dysmotility market segments, market trends and opportunities, and any further data you may need to thrive in the autoimmune gastrointestinal dysmotility industry. This autoimmune gastrointestinal dysmotility market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The autoimmune gastrointestinal dysmotility market size has grown strongly in recent years. It will grow from $1.82 billion in 2025 to $1.92 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to autoimmune disease diagnosis growth, gastroparesis prevalence, hospital gastroenterology expansion, immunosuppressive drug usage, rare disease awareness.
The autoimmune gastrointestinal dysmotility market size is expected to see strong growth in the next few years. It will grow to $2.63 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to early diagnostic improvements, personalized treatment approaches, long-term care demand, home-based nutrition therapy, autoimmune research expansion. Major trends in the forecast period include increased recognition of rare gastrointestinal disorders, growth in immunosuppressive treatment use, expansion of nutritional and dietary management, rising adoption of multidisciplinary care approaches, focus on long-term symptom management.
The growing number of clinical trials is expected to drive the expansion of the autoimmune gastrointestinal dysmotility market in the coming years. Clinical trials are research studies designed to assess the safety, efficacy, and optimal use of medical interventions-including drugs, biologics, devices, and treatment protocols-in human participants, with the goal of advancing medical knowledge and improving patient care. This increase in clinical trials is largely driven by expanded regulatory requirements for trial registration, rising investment in pharmaceutical research and development, and the accelerating pace of innovation in novel therapeutic approaches such as immunotherapies and biologics for autoimmune conditions affecting gastrointestinal motility. Clinical trials for autoimmune gastrointestinal dysmotility play a key role in advancing treatment options by systematically evaluating new immunosuppressive therapies, prokinetic agents, and biologics, identifying optimal treatment protocols, and establishing evidence-based strategies that support regulatory approval and clinical adoption of therapies targeting autoimmune-mediated gastrointestinal dysfunction. For example, in November 2025, ClinicalTrials.gov, a US-based clinical trials registry managed by the National Institutes of Health, reported that the total number of registered clinical studies reached 477,203 at the end of 2023 (including 437,493 cumulative and 39,710 new registrations) and increased to 520,877 at the end of 2024 (comprising 477,203 cumulative and 43,674 new registrations), reflecting a 9.1% year-on-year growth in total registered studies. Consequently, the rising number of clinical trials is fueling the growth of the autoimmune gastrointestinal dysmotility market.
The increasing prevalence of autoimmune disorders is expected to drive the growth of the autoimmune gastrointestinal dysmotility market in the coming years. Autoimmune diseases occur when the body's immune system mistakenly attacks its own healthy cells, tissues, or organs instead of defending against infections and foreign substances. This rise in autoimmune disorders is primarily attributed to a combination of genetic susceptibility and environmental triggers, which together disrupt immune regulation and increase the likelihood of the immune system targeting the body's own tissues. Autoimmune gastrointestinal dysmotility aids in identifying and managing underlying autoimmune conditions by detecting immune-mediated damage to the enteric nervous system, linking gastrointestinal symptoms to systemic autoimmune activity. For example, in October 2024, a comprehensive review published in Signal Transduction and Targeted Therapy, a journal by Nature, reported that approximately 8.4 million people worldwide suffer from rheumatoid arthritis, with incidence rates increasing by 2-3% annually; using a Markov model, the affected population is projected to reach 13.5-17.4 million by 2040. Consequently, the rising prevalence of autoimmune disorders is fueling the expansion of the autoimmune gastrointestinal dysmotility market.
The growing emphasis on personalized medicine is expected to drive the expansion of the autoimmune gastrointestinal dysmotility market in the coming years. Personalized medicine is a medical approach that customizes treatment and prevention strategies according to an individual's unique genetic profile, lifestyle, and environment. This trend is largely fueled by advancements in genomics, which allow for the precise identification of genetic variations and enable tailored therapies. Personalized medicine supports the management of autoimmune gastrointestinal dysmotility by customizing treatments based on a patient's genetic makeup and specific disease characteristics, improving therapeutic effectiveness and reducing side effects, thereby providing more targeted solutions for complex gastrointestinal disorders. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a notable increase from 12 approvals in 2022. Consequently, the rising focus on personalized medicine is fueling the growth of the autoimmune gastrointestinal dysmotility market.
Major companies operating in the autoimmune gastrointestinal dysmotility market are AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Zeria Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Dr. Falk Pharma GmbH, Rose Pharma LLC, Parvus Therapeutics Inc., CinDome Pharma Inc., Neurogastrx Inc., Renexxion LLC, ISOThrive Inc., Ambrose Healthcare Inc., AnTolRx Inc., Enteralia Bioscience S.r.l., Immunic Inc., Mozart Therapeutics Inc.
North America was the largest region in the autoimmune gastrointestinal dysmotility market in 2025. The regions covered in the autoimmune gastrointestinal dysmotility market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the autoimmune gastrointestinal dysmotility market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The autoimmune gastrointestinal dysmotility market consists of revenues earned by entities by providing services such as diagnostic testing, therapeutic treatments, clinical consultations, surgical interventions, rehabilitation and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The autoimmune gastrointestinal dysmotility market also includes sales of diagnostic kits, immunomodulatory drugs, prokinetic agents, and intravenous immunoglobulin (IVIG) therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Autoimmune Gastrointestinal Dysmotility Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses autoimmune gastrointestinal dysmotility market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for autoimmune gastrointestinal dysmotility ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The autoimmune gastrointestinal dysmotility market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
- Markets Covered:1) By Treatment Type: Medications; Surgical Interventions; Dietary Management; Physical Therapy
- 2) By Drug Class: Prokinetic Agents; Anti-Inflammatory Drugs; Immunosuppressive Drugs; Antibiotics
- 3) By Disease Type: Gastroparesis; Chronic Intestinal Pseudo-Obstruction (Cipo); Functional Dyspepsia; Irritable Bowel Syndrome (Ibs)
- 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacies; Other Distribution Channels
- 5) By End User: Hospitals; Clinics; Home Care Settings; Research Institutions
- Subsegments:
- 1) By Medications: Immunosuppressants; Corticosteroids; Prokinetic Agents; Antiemetics; Antispasmodics; Antibiotics
- 2) By Surgical Interventions: Gastrostomy; Jejunostomy; Colostomy; Ileostomy; Pyloroplasty; Colectomy
- 3) By Dietary Management: Enteral Nutrition; Parenteral Nutrition; Gluten-Free Diet; Elemental Diet; Small Frequent Meals
- 4) By Physical Therapy: Pelvic Floor Therapy; Abdominal Massage Therapy; Neuromuscular Electrical Stimulation (NMES); Biofeedback Therapy; Respiratory Muscle Training; Postural Training
- Companies Mentioned: AbbVie Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.; Chugai Pharmaceutical Co. Ltd.; Zeria Pharmaceutical Co. Ltd.; Ironwood Pharmaceuticals Inc.; Vanda Pharmaceuticals Inc.; Dr. Falk Pharma GmbH; Rose Pharma LLC; Parvus Therapeutics Inc.; CinDome Pharma Inc.; Neurogastrx Inc.; Renexxion LLC; ISOThrive Inc.; Ambrose Healthcare Inc.; AnTolRx Inc.; Enteralia Bioscience S.r.l.; Immunic Inc.; Mozart Therapeutics Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: Word, PDF or Interactive Report
- + Excel Dashboard
- Added Benefits
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
Table of Contents
1. Executive Summary
- 1.1. Key Market Insights (2020-2035)
- 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
- 1.3. Major Factors Driving the Market
- 1.4. Top Three Trends Shaping the Market
2. Autoimmune Gastrointestinal Dysmotility Market Characteristics
- 2.1. Market Definition & Scope
- 2.2. Market Segmentations
- 2.3. Overview of Key Products and Services
- 2.4. Global Autoimmune Gastrointestinal Dysmotility Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
- Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
- 2.4.4. Market Attractiveness Scoring and Interpretation
- 2.4.5. Strategic Implications and Recommendations
3. Autoimmune Gastrointestinal Dysmotility Market Supply Chain Analysis
- 3.1. Overview of the Supply Chain and Ecosystem
- 3.2. List Of Key Raw Materials, Resources & Suppliers
- 3.3. List Of Major Distributors and Channel Partners
- 3.4. List Of Major End Users
4. Global Autoimmune Gastrointestinal Dysmotility Market Trends And Strategies
- 4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Artificial Intelligence & Autonomous Intelligence
- 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.4 Industry 4.0 & Intelligent Manufacturing
- 4.1.5 Sustainability, Climate Tech & Circular Economy
- 4.2. Major Trends
- 4.2.1 Increased Recognition Of Rare Gastrointestinal Disorders
- 4.2.2 Growth In Immunosuppressive Treatment Use
- 4.2.3 Expansion Of Nutritional And Dietary Management
- 4.2.4 Rising Adoption Of Multidisciplinary Care Approaches
- 4.2.5 Focus On Long-Term Symptom Management
5. Autoimmune Gastrointestinal Dysmotility Market Analysis Of End Use Industries
- 5.1 Hospitals
- 5.2 Clinics
- 5.3 Home Care Settings
- 5.4 Specialty Gastroenterology Centers
- 5.5 Research Institutions
6. Autoimmune Gastrointestinal Dysmotility Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Autoimmune Gastrointestinal Dysmotility Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
- 7.1. Global Autoimmune Gastrointestinal Dysmotility PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 7.2. Global Autoimmune Gastrointestinal Dysmotility Market Size, Comparisons And Growth Rate Analysis
- 7.3. Global Autoimmune Gastrointestinal Dysmotility Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
- 7.4. Global Autoimmune Gastrointestinal Dysmotility Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Autoimmune Gastrointestinal Dysmotility Total Addressable Market (TAM) Analysis for the Market
- 8.1. Definition and Scope of Total Addressable Market (TAM)
- 8.2. Methodology and Assumptions
- 8.3. Global Total Addressable Market (TAM) Estimation
- 8.4. TAM vs. Current Market Size Analysis
- 8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Autoimmune Gastrointestinal Dysmotility Market Segmentation
- 9.1. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Medications, Surgical Interventions, Dietary Management, Physical Therapy
- 9.2. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Prokinetic Agents, Anti-Inflammatory Drugs, Immunosuppressive Drugs, Antibiotics
- 9.3. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Gastroparesis, Chronic Intestinal Pseudo-Obstruction (CIPO), Functional Dyspepsia, Irritable Bowel Syndrome (IBS)
- 9.4. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
- 9.5. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Hospitals, Clinics, Home Care Settings, Research Institutions
- 9.6. Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Immunosuppressants, Corticosteroids, Prokinetic Agents, Antiemetics, Antispasmodics, Antibiotics
- 9.7. Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Surgical Interventions, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Gastrostomy, Jejunostomy, Colostomy, Ileostomy, Pyloroplasty, Colectomy
- 9.8. Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Dietary Management, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Enteral Nutrition, Parenteral Nutrition, Gluten-Free Diet, Elemental Diet, Small Frequent Meals
- 9.9. Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Physical Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Pelvic Floor Therapy, Abdominal Massage Therapy, Neuromuscular Electrical Stimulation (NMES), Biofeedback Therapy, Respiratory Muscle Training, Postural Training
10. Autoimmune Gastrointestinal Dysmotility Market Regional And Country Analysis
- 10.1. Global Autoimmune Gastrointestinal Dysmotility Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- 10.2. Global Autoimmune Gastrointestinal Dysmotility Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
11. Asia-Pacific Autoimmune Gastrointestinal Dysmotility Market
- 11.1. Asia-Pacific Autoimmune Gastrointestinal Dysmotility Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 11.2. Asia-Pacific Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Autoimmune Gastrointestinal Dysmotility Market
- 12.1. China Autoimmune Gastrointestinal Dysmotility Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 12.2. China Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Autoimmune Gastrointestinal Dysmotility Market
- 13.1. India Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Autoimmune Gastrointestinal Dysmotility Market
- 14.1. Japan Autoimmune Gastrointestinal Dysmotility Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 14.2. Japan Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Autoimmune Gastrointestinal Dysmotility Market
- 15.1. Australia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Autoimmune Gastrointestinal Dysmotility Market
- 16.1. Indonesia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Autoimmune Gastrointestinal Dysmotility Market
- 17.1. South Korea Autoimmune Gastrointestinal Dysmotility Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 17.2. South Korea Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Autoimmune Gastrointestinal Dysmotility Market
- 18.1. Taiwan Autoimmune Gastrointestinal Dysmotility Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 18.2. Taiwan Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Autoimmune Gastrointestinal Dysmotility Market
- 19.1. South East Asia Autoimmune Gastrointestinal Dysmotility Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 19.2. South East Asia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Autoimmune Gastrointestinal Dysmotility Market
- 20.1. Western Europe Autoimmune Gastrointestinal Dysmotility Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 20.2. Western Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Autoimmune Gastrointestinal Dysmotility Market
- 21.1. UK Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Autoimmune Gastrointestinal Dysmotility Market
- 22.1. Germany Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Autoimmune Gastrointestinal Dysmotility Market
- 23.1. France Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Autoimmune Gastrointestinal Dysmotility Market
- 24.1. Italy Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Autoimmune Gastrointestinal Dysmotility Market
- 25.1. Spain Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market
- 26.1. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 26.2. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Autoimmune Gastrointestinal Dysmotility Market
- 27.1. Russia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Autoimmune Gastrointestinal Dysmotility Market
- 28.1. North America Autoimmune Gastrointestinal Dysmotility Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 28.2. North America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Autoimmune Gastrointestinal Dysmotility Market
- 29.1. USA Autoimmune Gastrointestinal Dysmotility Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 29.2. USA Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Autoimmune Gastrointestinal Dysmotility Market
- 30.1. Canada Autoimmune Gastrointestinal Dysmotility Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 30.2. Canada Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Autoimmune Gastrointestinal Dysmotility Market
- 31.1. South America Autoimmune Gastrointestinal Dysmotility Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 31.2. South America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Autoimmune Gastrointestinal Dysmotility Market
- 32.1. Brazil Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Autoimmune Gastrointestinal Dysmotility Market
- 33.1. Middle East Autoimmune Gastrointestinal Dysmotility Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 33.2. Middle East Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Autoimmune Gastrointestinal Dysmotility Market
- 34.1. Africa Autoimmune Gastrointestinal Dysmotility Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 34.2. Africa Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Autoimmune Gastrointestinal Dysmotility Market Regulatory and Investment Landscape
36. Autoimmune Gastrointestinal Dysmotility Market Competitive Landscape And Company Profiles
- 36.1. Autoimmune Gastrointestinal Dysmotility Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
- 36.2. Autoimmune Gastrointestinal Dysmotility Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
- 36.3. Autoimmune Gastrointestinal Dysmotility Market Company Profiles
- 36.3.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Chugai Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
37. Autoimmune Gastrointestinal Dysmotility Market Other Major And Innovative Companies
- Zeria Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Dr. Falk Pharma GmbH, Rose Pharma LLC, Parvus Therapeutics Inc., CinDome Pharma Inc., Neurogastrx Inc., Renexxion LLC, ISOThrive Inc., Ambrose Healthcare Inc., AnTolRx Inc., Enteralia Bioscience S.r.l., Immunic Inc., Mozart Therapeutics Inc.
38. Global Autoimmune Gastrointestinal Dysmotility Market Competitive Benchmarking And Dashboard
39. Key Mergers And Acquisitions In The Autoimmune Gastrointestinal Dysmotility Market
40. Autoimmune Gastrointestinal Dysmotility Market High Potential Countries, Segments and Strategies
- 40.1 Autoimmune Gastrointestinal Dysmotility Market In 2030 - Countries Offering Most New Opportunities
- 40.2 Autoimmune Gastrointestinal Dysmotility Market In 2030 - Segments Offering Most New Opportunities
- 40.3 Autoimmune Gastrointestinal Dysmotility Market In 2030 - Growth Strategies
- 40.3.1 Market Trend Based Strategies
- 40.3.2 Competitor Strategies
41. Appendix
- 41.1. Abbreviations
- 41.2. Currencies
- 41.3. Historic And Forecast Inflation Rates
- 41.4. Research Inquiries
- 41.5. The Business Research Company
- 41.6. Copyright And Disclaimer
